The light and the dark sides of Interleukin-10 in immune-mediated diseases and cancer
Standard
The light and the dark sides of Interleukin-10 in immune-mediated diseases and cancer. / Geginat, Jens; Larghi, Paola; Paroni, Moira; Nizzoli, Giulia; Penatti, Alessandra; Pagani, Massimiliano; Gagliani, Nicola; Meroni, Pierluigi; Abrignani, Sergio; Flavell, Richard A.
in: CYTOKINE GROWTH F R, Jahrgang 30, 08.2016, S. 87-93.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The light and the dark sides of Interleukin-10 in immune-mediated diseases and cancer
AU - Geginat, Jens
AU - Larghi, Paola
AU - Paroni, Moira
AU - Nizzoli, Giulia
AU - Penatti, Alessandra
AU - Pagani, Massimiliano
AU - Gagliani, Nicola
AU - Meroni, Pierluigi
AU - Abrignani, Sergio
AU - Flavell, Richard A
N1 - Copyright © 2016 Elsevier Ltd. All rights reserved.
PY - 2016/8
Y1 - 2016/8
N2 - Interleukin-10 (IL-10) is known to be a tolerogenic cytokine since it inhibits pro-inflammatory cytokine production and T cell stimulatory capacities of myeloid cells, such as macrophages and dendritic cells. In particular, it has a non-redundant tolerogenic role in intestinal immune homeostasis, since mice and patients with genetic defects in the IL-10/IL-10R pathway develop spontaneously colitis in the presence of a normal intestinal flora. However, IL-10 is also a growth and differentiation factor for B-cells, can promote autoantibody production and has consequently a pathogenic role in systemic lupus erythematosus. Moreover, IL-10 can promote cytotoxic T-cell (CTL) responses and this immunogenic activity might be relevant in type-1 diabetes and anti-tumor immune responses. This review summarizes these paradoxic effects of IL-10 on different types of immune responses, and proposes that different cellular sources of IL-10, in particular IL-10-secreting helper and regulatory T-cells, have different effects on B-cell and CTL responses. Based on this concept we discuss the rationales for targeting the IL-10 pathway in immune-mediated diseases and cancer.
AB - Interleukin-10 (IL-10) is known to be a tolerogenic cytokine since it inhibits pro-inflammatory cytokine production and T cell stimulatory capacities of myeloid cells, such as macrophages and dendritic cells. In particular, it has a non-redundant tolerogenic role in intestinal immune homeostasis, since mice and patients with genetic defects in the IL-10/IL-10R pathway develop spontaneously colitis in the presence of a normal intestinal flora. However, IL-10 is also a growth and differentiation factor for B-cells, can promote autoantibody production and has consequently a pathogenic role in systemic lupus erythematosus. Moreover, IL-10 can promote cytotoxic T-cell (CTL) responses and this immunogenic activity might be relevant in type-1 diabetes and anti-tumor immune responses. This review summarizes these paradoxic effects of IL-10 on different types of immune responses, and proposes that different cellular sources of IL-10, in particular IL-10-secreting helper and regulatory T-cells, have different effects on B-cell and CTL responses. Based on this concept we discuss the rationales for targeting the IL-10 pathway in immune-mediated diseases and cancer.
KW - Journal Article
U2 - 10.1016/j.cytogfr.2016.02.003
DO - 10.1016/j.cytogfr.2016.02.003
M3 - SCORING: Journal article
C2 - 26980675
VL - 30
SP - 87
EP - 93
JO - CYTOKINE GROWTH F R
JF - CYTOKINE GROWTH F R
SN - 1359-6101
ER -